Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RPC1063

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ozanimod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus
Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Review
2017
Review
2017
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis… Expand
  • figure 1
  • figure 2
  • table 1
  • table 3
Review
2017
Review
2017
Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, involve an inappropriate immune reaction in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Highly Cited
2016
Highly Cited
2016
Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P1) and receptor‐5 (S1P5) agonist with autoimmune disease‐modifying activity
Sphingosine1‐phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac function, and… Expand
Highly Cited
2016
Highly Cited
2016
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
BACKGROUND Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Review
2015
Review
2015
Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple… Expand
  • figure 1
  • figure 2
2015
2015
Digestive Disease Week
Digestive Disease Week (DDW) 2015 will take place in Washington, DC, from May 17 to 19. With more than 400 scientific sessions… Expand
2015
2015
445 The TOUCHSTONE Study: A Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis
 
2014
2014
Pharmacokinetics and Pharmacodynamics of RPC1063 and Its Metabolites in Healthy Adult Volunteers (P1.211)
OBJECTIVE: Evaluate the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of RPC1063 and its metabolites. BACKGROUND… Expand
2013
2013
Metabolites of RPC1063 Contribute to In Vivo Efficacy (P05.157)
OBJECTIVE: Identify metabolites of RPC1063 and determine their activity in vitro and in vivo. BACKGROUND: RPC1063 is a potent… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE